Editing Moberg Pharma AB
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
| Latest revision | Your text | ||
| Line 1: | Line 1: | ||
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden. | Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden. | ||
__INDEX__ | __INDEX__ | ||